Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines.
The formation and processing of neurotensin (NT) by three prostate cancer cell lines was investigated. Neurotensin (NT) immunoreactivity was detected in conditioned media and extracts of LNCaP cells. Using HPLC techniques, the immunoreactivity extracted from LNCaP cells coeluted with synthetic NT standard. Metalloendopeptidase 3.4.24.15 activity was detected in PC-3, DU-145 and LNCaP cells, whereas high levels of neutral endopeptidase 3.4.24.1 1 activity was detected only in LNCaP cells. NT was relatively stable when incubated with PC-3 or D-145 cells but was rapidly degraded by LNCaP cells to NT1-11 and NT1-10. Phosphoramidon inhibited the metabolism of NT by LNCaP cells. These data suggest that NT is present in and metabolized by LNCaP cellular enzymes.
Moody
T W
TW
Biomarkers and Prevention Research Branch, National Cancer Institute, Rockville, MD 20850, USA.
Mayr
C A
CA
Gillespie
T J
TJ
Davis
T P
TP
D002851:Chromatography, High Pressure Liquid; D010450:Endopeptidases / Q000378:metabolism*; D006020:Glycopeptides / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008666:Metalloendopeptidases / Q000378:metabolism; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism*; D015260:Neprilysin / Q000378:metabolism; D009496:Neurotensin / Q000302:isolation & purification / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism*; D011480:Protease Inhibitors / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000378:metabolism
D006020:Glycopeptides; D011480:Protease Inhibitors; D009496:Neurotensin; D010450:Endopeptidases; D008666:Metalloendopeptidases; D015260:Neprilysin; C022510:thimet oligopeptidase; C008890:phosphoramidon